Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti PieroCinzia AuriliaGabriella EgeoStefania ProiettiFlorindo D'OnofrioPaola TorelliMarco AguggiaDavide BertuzzoCinzia FinocchiMichele TrimboliSabina CevoliGiulia FiorentiniBianca OrlandoMaurizio ZuccoLaura Di ClementeIlaria CettaBruno ColomboMonica Laura Bandettini di PoggioValentina FavoniLicia GrazziAntonio SalernoAntonio CarnevaleMicaela RobottiFabio FredianiClaudia AltamuraMassimo FilippiFabrizio VernieriStefano Bonassinull nullPublished in: Journal of neurology (2024)
Two-thirds of patients not responding to anti-CGRP mAbs ≤ 24 weeks do respond later, while non-responders ≤ 48 weeks are quite rare (8.7%). These findings suggest to rethink the duration of migraine prophylaxis and the definition of resistant and refractory migraine, currently based on the response after 2-3 months of treatment.